Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise the scientific rationale for and mechanism of action of CD20 x CD3 bispecific antibodies for patients with various forms of non-Hodgkin lymphoma (NHL), and understand the similarities and differences among currently available and investigational agents in this class.
• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with available and investigational CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted antibody-drug conjugates (ADCs) for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available and emerging Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for chronic lymphocytic leukemia (CLL), and use this information to counsel patients regarding front-line treatment options.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with and the potential role of this strategy for patients with newly diagnosed CLL.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.